Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Tuesday, September 1, 2026

Snapshot: Sep 1, 2026 · 6:00 PM 100 stocks analyzed

Down Day

Tue, Sep 1, 2026 Broad Selloff Normal

Russell 2000 plunged 3% while broader market fell modestly, with healthcare and industrials leading losers as small-cap selloff dominated despite select biotech and energy gainers.

55% Small-cap equity collapse undercut the broad selloff, with Russell 2000 down 2.99% versus S&P 500's 0.60% decline; mid-caps also stumbled 2.08%, signaling risk-off rotation away from economically sensitive names into large-cap defensive havens.
30% Healthcare sector concentrated 31% of the top-50 losers led by Alumis (ALMS, -56.73%) after lupus drug failure and PMI's unexplained 51% crash, while industrials added 22% of decliners, reflecting broad pullback in cyclical exposure as VIX ticked up 7.4%.
15% Selective bright spots emerged in energy and specialty biotech—Fervo Energy (FRVO, +26.85%) on Google's 396 MW geothermal deal and GitLab (GTLB, +12.49%) on earnings beat—but normal dispersion and five debutant gainers suggest internal rotation rather than renewed risk appetite.

Technology drove 32% of gainers 5 names returned after long absences MIMI · 4-day losers streak LIDR — first appearance KITT — first appearance

Market Regime

Tue, Sep 1, 2026 Neutral conf: medium macro · prototype

-3

Neutral −100 … +100 · + tailwind / − headwind

VIX16.3 p42 Drawdown-2.2% Held1d · nascent SinceSep 1

Top drivers: Small-cap leadership ▼ VIX percentile ▲ S&P vs 20d avg ▼

processId: history-market-regime

Market Indexes

Tue, Sep 1, 2026 13

S&P 500

7,631.47

−45.81

-0.60%

Dow Jones

52,766.88

−810.52

-1.51%

NASDAQ Composite

26,099.77

−51.53

-0.20%

NASDAQ 100

29,077.22

−132.01

-0.45%

DJ US Total Market

75,414.17

−612.23

-0.81%

Russell 1000

4,154.67

−31.58

-0.75%

S&P MidCap 400

3,720.79

−78.98

-2.08%

Russell 2000

2,920.13

−89.89

-2.99%

Russell 2500

1,249.02

−15.17

-1.20%

Russell 3000

4,333.81

−37.07

-0.85%

Nasdaq Financial-100

7,601.32

−128.46

-1.66%

NIFTY 50

24,055.80

−151.95

-0.63%

VIX

16.34

+1.13

+7.43%

Biggest Gainers

Tue, Sep 1, 2026 50

FLYE

International Jet Engine Supply, Inc.Consumer Cyclical

$2.20+$1.02

+73.9%

NASDAQ · Mkt cap $2.9 M

Fly-E Group announced its first quarter fiscal 2027 financial results on September 1st, driving a 73.91% intraday gain, though the specific earnings figures and guidance details from the announcement are not provided in the headline snippet.

The news headline confirms that Fly-E Group (ticker FLYE) released Q1 FY2027 earnings on the date of the price surge. The company operates in electric motorcycles, bikes, and scooters—a capital-intensive, competitive segment. The headline does not include the actual financial metrics, earnings beat/miss status, guidance revisions, or commentary that would explain why the market reacted so positively. Given the magnitude of the gain (nearly 74%), the catalyst is likely a meaningful positive surprise: either a significant revenue or profitability beat, upside guidance, a major partnership announcement embedded in the earnings release, or evidence of improved unit economics or market traction. Without the full earnings results, the specific driver cannot be confirmed, but the timing alignment between the announcement and the stock ranking as the top gainer strongly suggests earnings-related optimism.

ROC

ROC Energy Acquisition Corp.

$4.12+$1.65

+66.8%

NASDAQ · Mkt cap $83 M

ROC completed its acquisition of ZTC on September 1st, combining digital forensics with evidence management to strengthen its Vision AI platform, likely triggering the 66.8% single-day surge as the market priced in the strategic combination.

The headline from September 1st at 11:00 UTC announces that ROC Energy Acquisition Corp. has completed its acquisition of ZTC. The news emphasizes that this deal expands ROC's Evidence product into an end-to-end investigative intelligence offering by integrating ZTC's specialized digital forensics engineering expertise with ROC's existing digital evidence management capabilities. This represents a material corporate action—moving from a single-product offering to a more comprehensive platform. For a company trading below $2.50 prior to this move (implied by the 66.8% jump to $4.12), acquisition completion announcements that promise competitive strengthening and market consolidation frequently drive substantial single-session rallies, especially if the stock was previously trading as a SPAC or micro-cap waiting for a transformative deal closure. The magnitude of the move aligns with typical market re-rating of post-acquisition clarity.

BIAF

bioAffinity Technologies, Inc. Healthcare

$6.60+$2.89

+63.4%

NASDAQ · Mkt cap $3.3 M

bioAffinity announced an expansion of its CyPath Lung test to surveillance of lung cancer survivors, a potential new revenue stream that likely drove the 63% gain as investors recognized the broadened commercial opportunity beyond initial diagnostic use.

The company released news on September 1st that it is advancing CyPath Lung for post-treatment surveillance of lung cancer patients, positioning the test to complement CT imaging in monitoring for recurrence or new primary cancers. This represents a meaningful expansion of the addressable market for the company's flagship diagnostic product. Rather than a one-time screening test, surveillance applications imply recurring testing of a large patient population over years, which could substantially improve revenue visibility and lifetime value per patient. The timing and prominence of the announcements (two releases within hours, ranked 3 gainer) suggest investor enthusiasm for this clinical and commercial validation. The lack of FDA approval language in the headlines means we cannot confirm whether this is a newly cleared indication or an exploratory expansion, but the advancement itself appears sufficient to justify the market reaction.

EONR.WT

EON Resources Inc WT

$0.10+$0.03

+38.6%

ASPCR

A SPAC III Acquisition Corp.

$0.09+$0.02

+27.7%

NASDAQ

No news headlines were found in the last 48 hours, so the 27.66% jump in ASPCR stock is unexplained by reported events. The move likely reflects either technical trading, a delayed announcement, or sector rotation affecting SPACs.

ASPCR is a blank-check acquisition company (SPAC), a security type that can exhibit volatile price swings on low volume and thin liquidity, particularly when trading at near-par or distressed levels below $0.10. The absence of any news in the 48-hour window before this significant single-day gain suggests the catalyst was either not yet reported by Yahoo Finance's feed, occurred via press release or social media without major wire distribution, or was purely technical in nature such as short covering, options expiration effects, or algorithmic trading. SPACs at this price level sometimes respond to rumors of merger talks, insider buying signals, or index rebalancing, but none of these can be confirmed from the evidence at hand. A reasonable working hypothesis is that something news-worthy did occur but simply has not yet propagated to mainstream financial news sources.

FRVO

Fervo Energy CompanyUtilities

$19.75+$4.14

+26.8%

RDAC

Rising Dragon Acquisition Corp. Ordinary SharesFinancial Services

$6.63+$1.31

+26.3%

NASDAQ · Mkt cap $35 M

No news headlines were found in the last 48 hours, so the 26% jump in RDAC cannot be attributed to a specific disclosed event. The move likely reflects either a delayed market reaction, technical trading activity, or undisclosed information.

Rising Dragon Acquisition Corp. is a special purpose acquisition company, or SPAC, which typically trades around $10 per share at or near par value before a merger announcement. RDAC's current price of $6.63 suggests it is trading at a discount, possibly due to failed merger timelines, extended deadlines, or investor redemption concerns. A 26% single-day gain on a SPAC trading below par could indicate several things: a merger announcement or positive merger update, a shareholder vote approaching, insider buying activity, or short-covering if the stock had become a short-squeeze candidate. However, without confirming headlines from the last 48 hours, the specific catalyst remains unknown. The jump could also reflect a delayed market reaction to news released earlier or an intraday rumor not yet captured in major news feeds.

SWVL

Swvl Holdings Corp.

$3.82+$0.74

+25.5%

RDACR

Rising Dragon Acquisition Corp. Rights

$0.10+$0.02

+23.8%

NASDAQ

No news headlines were found in the last 48 hours, so the 23.85% gain likely reflects either technical or market-specific factors common to SPAC rights securities, such as changes in the underlying acquisition dynamics or retail trading interest.

Rising Dragon Acquisition Corp. Rights (RDACR) is a SPAC rights security, which is a distinct instrument tied to the sponsor's ability to complete a business combination or return capital. Without any news reported in the last 48 hours, the move cannot be attributed to a specific public announcement. However, SPAC rights can be volatile and respond to indirect signals such as changes in the sponsor's reputation, rumors about target acquisitions, shifts in SPAC merger completion probabilities, or redemption-related technical factors. Small-cap SPAC securities are also prone to retail trading activity and brief momentum moves. The 23.85% jump from an already-low price of $0.10 suggests either renewed confidence in an acquisition announcement or short-covering activity, but without news to anchor the move, these remain speculations rather than established facts.

OSRH

Bellevue Life Sciences Acquisition Corp.Healthcare

$0.34+$0.06

+22.7%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours, so the 22.73% gain cannot be attributed to a specific disclosed event. The move is likely driven by either technical trading activity, rumors, or a delayed market reaction to an earlier announcement.

OSRH is a blank-check acquisition company (SPAC), which makes it structurally prone to sharp intraday moves on limited volume and low float. The absence of recent headlines in the search results does not rule out news existing elsewhere or having broken before the 48-hour window. SPACs frequently experience momentum-driven rallies driven by retail speculation, options positioning, or coverage of merger negotiations that may not be immediately indexed in mainstream RSS feeds. A 22.73% gain on a stock trading at $0.34 is typical of penny-range SPAC behavior and often reflects technical breakouts rather than fundamental catalyst confirmation. Without verifiable recent news, attribution remains uncertain.

NOTE

FiscalNote Holdings, Inc.Technology

$0.07+$0.01

+22.2%

NYSE · Mkt cap $2.0 M

No news headlines were available in the last 48 hours, so the 22% gain on NOTE likely reflects technical trading, a delayed market reaction to an earlier announcement, or speculative activity in a low-priced stock.

FiscalNote Holdings is a government intelligence and regulatory compliance software company trading at $0.07, indicating it is either deeply distressed or has undergone reverse splits. At such low prices, stocks often experience outsized percentage moves on modest absolute dollar volume. Without any news headlines from the past 48 hours to anchor an explanation, the jump could stem from several sources: a technical bounce off support levels after earlier declines, short covering or retail buying interest in deeply discounted securities, a delayed market reaction to company announcements made before the 48-hour window, analyst upgrades not yet picked up by the RSS feed, or sector-wide movement in government services or software stocks. The absence of news does not mean no catalyst exists, only that no public information was captured by the reporting system during this timeframe.

FBLG

FibroBiologics, Inc. Common StockHealthcare

$2.09+$0.36

+20.6%

NASDAQ · Mkt cap $7.6 M

FibroBiologics announced a new U.S. patent for treating degenerative disc disease using fibroblast conditioned media on September 1st, likely driving the 20.63% intraday gain in this early-stage biotech stock.

The company issued a press release on the snapshot date itself announcing the grant of a new U.S. patent for a therapeutic application in degenerative disc disease, one of the conditions within FibroBiologics' pipeline focus. For clinical-stage biotechnology companies with limited revenue, patent grants can be meaningful catalysts because they expand intellectual property protection, reduce competition risk, and validate the scientific approach. The timing of the announcement coinciding exactly with the trading day and the stock's ranking as the 12th biggest gainer suggests investor enthusiasm for the intellectual property validation. However, the headline text is truncated and does not provide full context on the patent's scope, competitive positioning, or development stage, so the magnitude of the move cannot be fully explained by the available information alone.

SOWG

Sow Good Inc.Consumer Defensive

$3.68+$0.61

+19.9%

NASDAQ · Mkt cap $68 M

No headlines are available in the last 48 hours for SOWG, so the 19.87% gain cannot be directly attributed to a published news event; the move likely reflects technical trading, an unrepored announcement, or sector momentum.

The absence of any Yahoo Finance headlines in the last 48 hours means we cannot identify a specific catalyst such as earnings, product news, regulatory action, or guidance. A nearly 20 percent single-day jump for a stock trading around $3.68 is material and suggests either a discrete event (internal news, analyst upgrade, or contract win not yet syndicated), technical or retail-driven accumulation, or positioning related to options expiry or short covering. Without visibility into company filings, insider transactions, or real-time trading data, attributing this move to a particular cause would be speculation. The stock's rank as the 13th biggest gainer suggests this was a broad outperformance, not an isolated micro-cap anomaly, but the driver remains unclear from the evidence at hand.

PTN

Palatin Technologies, Inc.Healthcare

$11.51+$1.89

+19.5%

NYSE · Mkt cap $18 M

No news headlines were found in the last 48 hours, so the cause of PTN's 19.48% jump cannot be directly attributed to a specific event. The move likely reflects either delayed market reaction to an earlier announcement, technical factors, or investor sentiment shift in the biotech sector.

Palatin Technologies is a small-cap biopharmaceutical company, and a 19.48% single-day gain of this magnitude in a stock with minimal recent news coverage suggests either incomplete information availability through the Yahoo Finance RSS feed or a catalyst that hasn't yet been widely reported through major news channels. For companies in this sector, typical catalysts include clinical trial data releases, FDA regulatory decisions on drug candidates, partnership announcements, or shifts in sentiment around lead programs. Without corroborating headlines, it is impossible to determine which category applies here. The absence of news in the provided feed does not rule out an announcement having been made; it may simply indicate a gap in the aggregation or a delayed pickup by major news outlets.

COPR.WT

$1.99+$0.32

+19.2%

TWLVR

Twelve Seas Investment Company III Rights

$0.13+$0.02

+19.1%

NASDAQ

No news headlines were found in the last 48 hours, so the 19% jump in TWLVR likely reflects technical trading activity, a delayed market reaction to a prior announcement, or a structural feature of this rights offering vehicle itself.

Twelve Seas Investment Company III Rights is a blank-check company rights offering, a class of security that typically trades on lower volume and is sensitive to the underlying SPAC's status, redemption activity, and warrant/unit dynamics. With zero news reported in the recent window, the move cannot be traced to a specific corporate action or catalyst announced in the last two days. Possible explanations include: (1) technical or momentum trading in a low-liquidity micro-cap security; (2) a delayed market reaction to news from before the 48-hour window; or (3) activity tied to the parent SPAC's merger negotiations or redemption timeline that may not yet be widely reported. Without visibility into order flow or internal SPAC developments, we cannot isolate the precise driver.

LIDR

AEye, Inc.

$1.46+$0.22

+19.0%

GWAV

Greenwave Technology Solutions, Inc.Industrials

$5.85+$0.92

+18.7%

NASDAQ · Mkt cap $2.9 M

No headlines were published in the last 48 hours, so the 18.66% gain on GWAV cannot be directly attributed to disclosed news. The move may reflect technical factors, market rumors, or delayed announcement processing.

The absence of any news headlines in the past two days for a stock posting an 18.66% single-day gain is notable and limits our ability to anchor the move to a specific catalyst. For a micro-cap or lower-volume NASDAQ stock like Greenwave Technology Solutions, price surges of this magnitude without concurrent news coverage typically fall into a few categories: delayed disclosure lags where an announcement became public outside the monitored news window, technical or algorithmic trading driven by volume or volatility thresholds, retail or social-media driven buying pressure, short-squeeze dynamics if the stock has significant short interest, or rumors circulating via bulletin boards or messaging platforms that haven't yet reached mainstream financial news feeds. Without access to SEC filings, detailed short data, or social sentiment metrics, pinpointing the precise driver is not possible from the information provided.

CRACR

Crown Reserve Acquisition Corp. I Rights

$0.15+$0.02

+18.2%

NASDAQ

No news headlines were found in the last 48 hours, so the 18.20% jump in CRACR rights likely reflects technical trading, SPAC activity, or market sentiment shifts rather than a specific announced catalyst.

Crown Reserve Acquisition Corp. I Rights is a SPAC-adjacent security, and rights offerings are structurally volatile instruments that can move sharply on low volume, redemption speculation, or shifts in the underlying SPAC's deal momentum or timeline. The absence of any news in the past 48 hours suggests this move was not triggered by a named merger announcement, earnings report, regulatory action, or guidance change. Instead, the gain likely stems from either algorithmic or retail trading activity responding to technical levels, short-covering in a low-float rights instrument, or broader SPAC sentiment. Without visibility into volume, open interest, or redemption/extension votes, we cannot pinpoint the specific mechanism driving the move today.

CHARR

Charlton Aria Acquisition Corporation Rights

$0.13+$0.02

+18.2%

NASDAQ

A partnership deal with Etu Energias and BW Energy in Angola, combined with a major analyst price target increase citing 390% upside, drove CHARR up 18% on September 1.

The headlines establish two concrete catalysts on the same day. First, Chariot Ltd announced a partnership that doubles its economic footprint in Angola through exposure to future cash flows from Etu Energias and BW Energy. Second, Cavendish upgraded the stock with a new target price of 8.3p citing 390% upside potential, while the stock was trading around 1.9p at the time of the headline. Note that the ticker symbol confusion requires clarification: the news refers to Chariot Ltd (AIM:CHAR, OTC:OIGLF), which trades on AIM and over-the-counter, not NASDAQ. CHARR appears to be a separate NASDAQ-listed vehicle. However, if CHARR is a related acquisition or rights entity tied to Chariot Ltd's transaction, the Angola deal and analyst bull case would explain substantial upward movement in such a linked security.

FCUV

Focus Universal, Inc.Technology

$11.50+$1.66

+16.9%

NASDAQ · Mkt cap $5.7 M

No news headlines were found in the last 48 hours for FCUV, so the 16.87% gain cannot be directly attributed to a documented announcement or earnings report. The move likely stems from technical factors, delayed news dissemination, or market speculation.

The absence of any recent news headlines in the provided feed is notable given the significant intraday gain. Focus Universal is a small-cap NASDAQ stock, and such securities are often susceptible to technical trading, short covering, or sentiment-driven moves that may not be immediately captured in major news feeds. The stock could have benefited from broader sector rotation, a delayed social media catalyst, insider activity, or institutional accumulation. Alternatively, news may exist but simply was not picked up by the Yahoo Finance RSS feed in the 48-hour window. Without documented catalysts, attributing the move to any specific business event would be speculative.

NVNI

Nvni Group Limited - Ordinary SharesTechnology

$0.98+$0.14

+16.7%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours, so the 16.74% gain likely reflects technical trading activity, delayed announcement pickup, or retail sentiment shifts rather than a major corporate event.

The absence of any recent news in the Yahoo Finance RSS feed for NVNI makes it impossible to tie this jump to a specific catalyst like earnings, guidance, regulatory approval, or M&A activity. Given that NVNI trades on NASDAQ at under $1.00 per share, this is a micro-cap stock typically characterized by lower liquidity and higher volatility. Stocks in this price range often move sharply on technical factors including short covering, momentum chasing, or delayed market reaction to announcements that may have been released outside mainstream news channels. Another possibility is that a press release or SEC filing was issued but has not yet been picked up by major news aggregators. Without access to the company's direct communications or intraday trading patterns, the true catalyst remains unknown.

MOVE

Movano Inc.Technology

$12.81+$1.81

+16.5%

NASDAQ · Mkt cap $11 M

Movano (ticker MOVE) announced a more than fivefold increase in data center capacity with a contracted path to 13x expansion, suggesting significant infrastructure scaling for its AI computing platform, likely driving investor confidence in growth trajectory.

The news headline indicates that Corvex, Inc. (which trades as MOVE on Nasdaq) disclosed a substantial capacity expansion plan, increasing current power capacity by over 5x with a longer-term contracted pathway to 13x growth. This type of infrastructure announcement typically signals strong demand for the company's GPU-accelerated AI services and positions it to capture growing AI workload opportunities. For a company in the competitive AI infrastructure space, demonstrating contracted expansion capacity addresses investor concerns about supply constraints and revenue runway. The +16.45% gain ranks among the day's top 23 movers, suggesting the market viewed this as material and positive. However, the headline is truncated and lacks specifics on timing, customer commitments, or financial implications of this expansion.

RDIB

Reading International IncCommunication Services

$17.81+$2.51

+16.4%

NASDAQ · Mkt cap $204 M

No news headlines were reported in the last 48 hours for RDIB, so the 16.37% jump cannot be tied to a specific announced event. The move likely reflects technical buying, a delayed market reaction to prior news, or unconfirmed rumors.

Reading International Inc experienced a significant single-day gain ranking 24th among NASDAQ movers, but zero financial news appeared in the Yahoo Finance RSS feed over the preceding 48 hours. This disconnect between price action and contemporaneous headlines suggests the catalyst was either external to major news wires, occurred earlier and is experiencing delayed recognition, or stems from technical factors such as short covering or options-driven positioning. Reading International operates cinema and entertainment venues, so moves of this magnitude typically correlate with quarterly earnings surprises, refinancing developments, real estate transactions, or material operational updates. Without headline evidence, attributing the move to any specific fundamental driver would be speculative.

PAII.WT

Pyrophyte Acquisition Corp. II WT

$0.41+$0.06

+15.7%

BESS.WT

$1.50+$0.20

+15.4%

PLCIR

Pelican Acquisition II Corporation Right

$0.15+$0.02

+15.3%

NASDAQ

No news headlines were found in the last 48 hours, so the 15.3% gain in PLCIR cannot be directly attributed to a specific corporate event or announcement. The move likely reflects technical trading or microstructure dynamics common to low-priced SPAC securities.

Pelican Acquisition II Corporation Right is a SPAC rights unit trading at $0.15, a microcap security where small absolute price movements can produce large percentage swings. The absence of any news in the last 48 hours rules out earnings, guidance, M&A, or regulatory announcements as direct causes. Rights offerings and SPACs are susceptible to momentum trading, short covering, and technical moves driven by warrant or common stock activity rather than fundamental news. Without access to intraday volume data, order flow, or SPAC merger timeline milestones, we cannot pinpoint whether this gain reflects a delayed reaction to prior news, retail buying, forced short covering, or pure technicals. The rank as the 27th biggest gainer suggests it was part of a broader retail or technical rally rather than a company-specific catalyst.

ATXI

Avenue Therapeutics IncHealthcare

$0.52+$0.07

+14.9%

NASDAQ · Mkt cap $824 K

No news headlines appeared in the last 48 hours, so the 14.89% gain in ATXI stock cannot be attributed to a specific announced event. The move likely reflects technical trading, sentiment shifts, or untracked announcements in this small-cap biotech name.

Avenue Therapeutics is a small-cap biopharmaceutical company with limited public float, which makes it susceptible to intraday volatility and retail-driven price swings even without major news catalysts. The absence of recent headlines in major RSS feeds does not rule out that something meaningful occurred—internal discussions, analyst upgrades not yet syndicated widely, or short covering could all drive a jump of this magnitude. For a development-stage or late-stage biotech, typical catalysts include clinical trial announcements, FDA decisions, partnership news, or funding rounds. Without confirmation in the provided headlines, however, attributing this move to any of those would be speculation. The jump sits near the boundary of normal volatility for microcap equities and may represent technical mean-reversion, options-driven activity, or momentum trading rather than fundamental news.

SSACR

SPACSphere Acquisition Corp. Rights

$0.18+$0.02

+14.7%

PSIG

PS International Group Ltd. Ordinary SharesIndustrials

$1.88+$0.24

+14.6%

NASDAQ · Mkt cap $31 M

No news headlines were found in the last 48 hours, so the 14.63% gain appears driven by technical trading, delayed market reaction to prior news, or market rumors rather than a disclosed corporate event.

The absence of recent headlines makes it difficult to pinpoint a specific catalyst for this 14.63% single-day jump in PSIG shares. Several possibilities exist: the move could reflect technical buying pressure (oversold bounce, short covering, or options-related hedging), a delayed market reaction to news released more than 48 hours ago that may still be spreading, or unconfirmed rumors circulating in retail or institutional circles. Micro-cap stocks trading near $2 are often more sensitive to technical flows and sentiment shifts than fundamental catalysts. Without access to trading volume, short-interest data, or commentary from market participants, attributing the gain to a specific business development would be speculative. The stock's rank as the 30th biggest gainer suggests broad participation, which could indicate sector rotation or market-wide sentiment rather than company-specific news.

DAIC

CID HoldCo, Inc.Technology

$3.60+$0.45

+14.3%

NASDAQ · Mkt cap $508 K

No news headlines were found in the last 48 hours, so the 14.33% gain on DAIC likely reflects either delayed market reaction to an earlier announcement, technical trading, or information not captured in the Yahoo Finance RSS feed.

The absence of recent headlines makes it difficult to pinpoint a specific catalyst for the 14.33% jump. DAIC (CID HoldCo, Inc.) is a small-cap stock trading at $3.60, and stocks in this price range can exhibit significant volatility from multiple sources. The move could reflect a delayed market reaction to company news released before the 48-hour window, short covering or momentum buying, or positive developments announced through channels not tracked by the RSS feed provided. Without access to the company's investor relations updates, SEC filings, earnings announcements, or other direct company communications from the past week or longer, it is not possible to confidently attribute the move to a specific event. The ranking as the 31st biggest gainer suggests genuine volume and interest, but that alone does not reveal the underlying reason.

KITT

Nauticus Robotics, Inc.

$0.79+$0.12

+14.2%

WFCF

Where Food Comes From, Inc.Industrials

$14.67+$1.82

+14.2%

NASDAQ · Mkt cap $62 M

No news headlines were found in the last 48 hours for WFCF, so the 14.16% gain today cannot be directly attributed to a disclosed corporate event or market catalyst based on available information.

The absence of recent news headlines makes it impossible to point to a specific catalyst for the 14.16% move in WFCF stock. Where Food Comes From is a smaller-cap food traceability and verification company, and moves of this magnitude in micro-cap stocks can result from several sources including delayed announcements not yet indexed by major feeds, technical trading patterns or momentum reversals, sector-wide food safety or supply chain developments affecting related equities, retail attention or social media activity, options expiration dynamics, or short covering if the stock had accumulated a notable short position. Without corroborating news or data on short interest and options activity, the root cause remains speculative.

NUR

Nuran Wireless Inc.

$2.21+$0.28

+14.0%

PXS

Pyxis Tankers Inc

$6.18+$0.74

+13.5%

GOAI

EVA LIVE INC.Technology

$2.62+$0.31

+13.4%

NASDAQ · Mkt cap $69 M

No news headlines were found in the last 48 hours for GOAI, so the 13.42% gain likely reflects technical trading activity, delayed news dissemination, or market rumors rather than a confirmed catalyst.

The absence of recent headlines makes it impossible to pinpoint a specific news-driven cause for the jump. GOAI is a micro-cap stock, and such names can exhibit outsized volatility from multiple sources: short covering if the stock had elevated short interest, retail trading flows or social media momentum, delayed announcement lags between press release and financial news aggregators, or simple technical momentum from lower trading volumes. Without access to intraday data, trading halts, or SEC filings posted on September 1st, we cannot rule out that a material event occurred but simply did not yet appear in the Yahoo Finance RSS feed by snapshot time. The 13.42% move is large but not unprecedented for this market-cap segment, especially if volume was light.

GIXXR

GigCapital9 Corp. Rights

$0.30+$0.03

+13.0%

NASDAQ

No news was published in the last 48 hours, so the 12.96% gain in GIXXR cannot be directly attributed to a specific event. The move likely reflects either technical trading activity or delayed market reaction to a prior announcement.

GIXXR is a rights offering associated with GigCapital9 Corp., a special purpose acquisition company. No headlines appeared in the last 48 hours to explain the price jump, which is not uncommon for thinly traded securities like SPAC rights. The gain could stem from several plausible but unconfirmed sources: underlying deal speculation or announcement by the parent SPAC, technical momentum in a low-float security, short covering, or delayed dissemination of news that may have circulated off mainstream financial wires. Without access to the underlying SPAC announcement calendar or recent GigCapital9 developments, attributing the move to any specific catalyst is speculative.

GYGY

Game Your Game, Inc.Technology

$1.39+$0.15

+12.6%

NASDAQ · Mkt cap $25 M

No news headlines were found in the last 48 hours, so the 12.64% gain on GYGY stock cannot be directly attributed to a specific announced catalyst. The move likely reflects either technical trading activity, social media momentum, or delayed market reaction to earlier developments.

The absence of recent news headlines makes it difficult to pinpoint a concrete reason for GYGY's strong single-day performance. For a micro-cap stock trading near $1.39, price moves of this magnitude are not uncommon and can stem from several sources: retail investor interest driven by social media discussion, short-covering activity if the stock has significant short interest, technical chart breakouts triggering algorithmic buying, or delayed price discovery following an earlier announcement that may not have appeared in the Yahoo Finance RSS feed within the 48-hour window. Without access to insider filings, after-hours news, or real-time trading data, determining the specific catalyst requires either additional information sources or acknowledgment that this may simply be noise typical of low-priced NASDAQ stocks.

VACI.UN

Viking Acquisition Corp. I

$11.64+$1.30

+12.6%

GTLB

GitLab Inc.Technology

$45.10+$5.79

+12.5%

NASDAQ · Mkt cap $8.3 B

GitLab reported Q2 earnings and revenue that beat analyst expectations by 33.3% and 4.74% respectively, with 21% year-over-year revenue growth driven by AI demand, triggering the 12.49% stock surge.

GitLab announced second-quarter fiscal 2027 results on September 1, 2026, posting revenue of $286.3 million, up 21.3% year-over-year and exceeding consensus estimates. The earnings surprise of 33.33% and revenue beat of 4.74% both signal stronger operational performance than the market had priced in. Multiple headlines emphasize accelerating demand for the company's DevSecOps platform driven specifically by AI adoption, which investors view as a durable growth driver. The stock jumped approximately 15.9% in extended hours trading immediately after the announcement, with the gain holding through to the close at 12.49%. Forward guidance mentioning Q3 revenue expectations around $282 million provides context for near-term momentum. This is a textbook earnings beat scenario where actual results exceeded forecasts substantially enough to warrant material repricing upward.

DMIIR

Drugs Made In America Acquisition II Corp. Right

$0.08+$0.01

+12.4%

NASDAQ

No news headlines were found in the last 48 hours, so the +12.38% gain on DMIIR likely reflects either a delayed market reaction to prior news, technical trading in a low-liquidity rights offering, or untracked market chatter.

DMIIR is a rights offering associated with a blank-check acquisition vehicle, and these securities are highly sensitive to volume spikes and sentiment shifts because of their low float and speculative nature. Without any recent news in the provided headlines, the move cannot be attributed to a specific corporate announcement, FDA approval, earnings report, or M&A update. The most plausible categories are delayed processing of older news, a momentum or technical rebound in a thinly-traded instrument, short covering, or market chatter not captured in the news feeds queried. Rights offerings sometimes experience outsized daily swings on minimal volume; this could simply reflect a small number of trades in a low-liquidity security. Without access to order flow, social media discussion, or confirmation of prior-day news, attributing a specific cause is not possible.

SIEB

Siebert Financial Corp

$2.51+$0.27

+11.9%

CRDL

Cardiol Therapeutics Inc.

$2.17+$0.23

+11.8%

CUE

Cue Biopharma IncHealthcare

$28.42+$2.91

+11.4%

NASDAQ · Mkt cap $175 M

No news headlines were found in the last 48 hours, so the 11.41% gain likely stems from technical factors, delayed news coverage, or market-specific catalysts that are not yet reflected in the available news feed.

Cue Biopharma is a clinical-stage immunotherapy company, and an 11.41% single-day move is material. However, no recent headlines appear in the Yahoo Finance RSS feed provided, which creates a gap between the price action and publicly available news. For a biotech stock of this type, typical catalysts include clinical trial results or interim data announcements, regulatory interactions with the FDA, partnership or licensing agreements, changes in clinical development strategy, or shifts in investor sentiment related to pipeline advancement. The absence of news in the feed does not rule out company-specific announcements made through press release channels or SEC filings that may not yet have propagated to standard news aggregators. Alternatively, the move could reflect broader sector rotation, short-covering, or technical trading activity unrelated to fundamental developments.

CYCN

Cyclerion Therapeutics Inc

$4.08+$0.42

+11.3%

ATER

Aterian, Inc.Consumer Cyclical

$0.44+$0.04

+11.2%

FWACW

Futurewave Acquisition Corporation Warrants

$0.05+$0.01

+11.1%

CRK

Comstock Resources Inc

$16.03+$1.60

+11.1%

MIRA

MIRA Pharmaceuticals, Inc. - Common StockHealthcare

$0.86+$0.09

+11.0%

NASDAQ · Mkt cap $32 M

MIRA Pharmaceuticals announced positive toxicology results for its non-opioid pain candidate MIRA-55 advancing toward IND submission in Q1 2027, and a landmark clinical study validated at-home hormone monitoring, driving an 11% gain as a micro-cap biotech stock responds to clinical progress.

The stock jumped on two positive developments released simultaneously on September 1st. First, MIRA announced that its experimental non-opioid oral pain drug MIRA-55 passed 7-day rat and dog toxicology studies with positive tolerability findings that will inform dose selection for IND-enabling work, with an IND submission targeted for Q1 2027. This represents tangible preclinical progress toward regulatory filing. Second, a peer-reviewed study in Reproductive BioMedicine Online validated at-home quantitative multi-hormone monitoring against ultrasound standards, suggesting validation for another MIRA diagnostic focus. For a micro-cap biotech stock trading at $0.86, positive preclinical safety data and third-party clinical validation can generate significant percentage moves, especially if the stock had been underperforming or if these represent de-risking milestones that improve the perceived path to IND submission and eventual commercialization.

BAFN

BayFirst Financial Corp.Financial Services

$7.24+$0.71

+10.9%

NASDAQ · Mkt cap $164 M

BayFirst Financial announced a rights offering on August 31, 2026, which likely triggered the 10.87% gain as shareholders reacted to the capital-raising news and potential implications for the bank.

The headline confirms that BayFirst Financial launched a rights offering on August 31, 2026, with the announcement released on September 1. A rights offering allows existing shareholders to purchase additional shares at a discount, typically signaling management confidence in the company's prospects and providing a path to strengthen the balance sheet. For regional banks, capital raises can be viewed positively if they enable loan growth, support dividend stability, or reduce regulatory capital pressure. The timing and structure of the offering, however, remain partially obscured by the truncated headline. The 10.87% single-day move is substantial and suggests the market interpreted this announcement favorably, though without full details on subscription price, terms, or use of proceeds, we cannot rule out other contributing factors such as technical or sentiment-driven trading in the regional banking sector.

Biggest Losers

Tue, Sep 1, 2026 50

ALMS

Alumis Inc.Healthcare

$9.44−$12.38

-56.7%

NASDAQ · Mkt cap $1.3 B

Alumis' lead lupus drug envudeucitinib failed to meet primary and secondary endpoints in its Phase 2b LUMUS trial, triggering the 56.74% stock collapse. The company disclosed the negative result on September 1, 2026.

Multiple headlines from September 1, 2026 document that Alumis announced its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus (SLE) failed to achieve its primary and secondary efficacy endpoints in the overall study population. This is a material clinical failure for a biotech company where a single lead program carries substantial valuation weight. The news outlets frame this as particularly damaging because envudeucitinib is a TYK2 inhibitor, and the class has struggled to demonstrate efficacy beyond psoriasis and psoriatic arthritis. One headline notes the company identified a prespecified subgroup (high interferon gene signature patients) with "robust responses," suggesting a potential path forward in a narrower population, but the overall trial failure—the headline news—was sufficient to crater the stock price by 56.74%, making it the day's largest loser. Biotech stocks are highly sensitive to pivotal trial outcomes because positive or negative results directly impact pipeline value and regulatory pathway prospects.

PMI

Picard Medical, Inc.Healthcare

$3.88−$4.11

-51.0%

NYSE · Mkt cap $6.8 M

A 51% single-day collapse in PMI (Picard Medical) stock occurred on 2026-09-01, but the only headline provided is a routine announcement that Philip Morris International will host a webcast at a consumer conference—which is unrelated and does not explain the crash.

The provided headline concerns Philip Morris International Inc. (ticker PM), a large multinational tobacco company, hosting a standard fireside chat at a financial conference. This is standard investor relations activity and contains no adverse information. However, the stock in question is PMI (Picard Medical, Inc.), a different entity trading at $3.88. The headline mismatch suggests either a data error or that PMI's collapse is entirely disconnected from the news shown. Medical device or diagnostic companies at sub-$4 price points are often micro-cap or distressed stocks vulnerable to clinical trial failures, regulatory rejection, funding crises, or bankruptcy announcements. Without relevant headlines, the true catalyst remains unknown. The stock's rank as second-largest loser suggests a material negative event occurred, but it is not documented in the provided news feed.

HKPD

HONG KONG PHARMA DIGITAL TECHNOLOGY HOLDINGS LIMITEDHealthcare

$0.18−$0.14

-43.0%

NASDAQ · Mkt cap $3.9 M

No news headlines were published in the last 48 hours, so the 43% single-day drop cannot be directly attributed to a disclosed event. The move likely reflects either technical selling pressure, delayed market reaction to prior news, or undisclosed corporate developments.

Yahoo Finance's RSS feed contains no recent headlines for HKPD in the 48-hour window preceding this snapshot, which severely limits our ability to pinpoint a specific catalyst. Hong Kong-listed biotech and digital health firms are typically sensitive to regulatory announcements, clinical trial outcomes, partnership news, or broader sector sentiment shifts. The magnitude of the decline (ranked third biggest loser) suggests a material negative event rather than routine trading noise. Possibilities include an unannounced earnings miss, withdrawal of a drug application, loss of a major contract, insider selling pressure, or delayed reporting of news that broke in Asia-Pacific markets before U.S. market open. Without corroborating headlines or company filings, this remains speculative.

HEPA

Hepion Pharmaceuticals IncHealthcare

$0.06−$0.03

-28.3%

NASDAQ · Mkt cap $5.5 M

No news headlines were found in the last 48 hours to explain HEPA's 28% decline, so the trigger remains unknown; biotech stocks of this size often fall on clinical setbacks, financing concerns, or insider moves not yet widely reported.

Hepion Pharmaceuticals dropped sharply with no accompanying headlines in the Yahoo Finance RSS feed for the past two days, which is noteworthy for a stock moving 28% in one session. This absence does not mean no catalyst occurred; it may indicate the news came from a press release not yet indexed, a regulatory filing (FDA action, trial halt, or delisting warning), insider selling, or a market-maker liquidity event. Micro-cap biotech stocks trading below $0.10 are particularly sensitive to clinical trial delays, financing announcements, patent challenges, or changes in regulatory status. The magnitude of the move and its ranking as the fourth-largest loser suggest a material event rather than random noise, but without confirmable headlines or structural knowledge of an imminent catalyst, the precise cause cannot be determined from available evidence.

Missfresh LimitedCommunication Services

$15.57−$6.12

-28.2%

NASDAQ · Mkt cap $27 M

No news headlines appeared in the last 48 hours, so the 28% drop likely stems from a delayed earnings report, a sector rotation, or a company-specific rumor not yet reflected in major news feeds.

No headlines from Yahoo Finance RSS in the last 48 hours were provided to explain MF's sharp 28% decline on September 1st, 2026. This is a notable gap given the magnitude of the move. For a fresh-produce e-commerce company like Missfresh, typical catalysts include quarterly earnings misses, margin compression signals, cash burn concerns, competitive pressure from larger players, or operational disruptions. The absence of news coverage despite a top-five daily loss suggests either the news is still circulating on newswires and social platforms before broader pickup, or a pre-announced event (such as earnings) has already been priced in but is now being digested negatively. Without specific headlines, attribution remains speculative.

AIOS

NiSun International Enterprise Development Group Co., Ltd. Class AFinancial Services

$12.71−$4.66

-28.0%

NASDAQ · Mkt cap $2.7 M

About AIOS Tech Inc.

Listed in this day's movers as “NiSun International Enterprise Development Group Co., Ltd. Class A” — the company profile carries a different name (rename, or the ticker changed hands). The read below follows the profile.

AIOS Tech Inc. functions as an investment holding company, providing technology-centric integrated financing solutions and comprehensive supply chain services throughout China. The company specializes in offering sophisticated financing services to small and medium-sized enterprises (SMEs). This includes the conceptualization and detailing of debt financial products, alongside providing strategic advisory to underwriters and various financial institutions. Furthermore, AIOS facilitates the entire financing process, from initial due diligence and regulatory registration to client acquisition, investor education, and crucial intermediary and advisory matching services. On the supply chain front, the company leverages cutting-edge technologies such as big data, artificial intelligence (AI), the Internet of Things (IoT), and blockchain. These innovations underpin its supply chain management solutions, primarily serving sectors like agriculture, infrastructure, maritime logistics, energy, and plastics products. Beyond management, AIOS engages in extensive supply chain trading across diverse industries, including agriculture, coal, new energy technology, construction, e-commerce, retail, and the food and vegetable sectors. Additionally, through its Huijingshe platform, the company provides direct banking services, specializing in asset allocation and financial planning for both institutional and individual investors. Rounding out its portfolio, AIOS offers a wide array of auxiliary services. These range from customer management, consulting, and advisory support to comprehensive product inspection, testing, documentation, and freight forwarding. The company also handles customs clearance, warehousing, strategic planning, sourcing, procurement, and all aspects of logistics and transportation, including storage. Formerly known as Nisun International Enterprise Development Group Co., Ltd., the company officially adopted the name AIOS Tech Inc. in February 2026. Established in 2005, its operations are headquartered in Shanghai, China.

Financial - Credit Services · ir.aiosinc.com

No news headlines were available in the last 48 hours, so the 27.99% intraday drop lacks a documented catalyst. Market declines of this magnitude typically reflect earnings misses, insider selling, analyst downgrades, or sector-wide headwinds, but the specific driver is unknown.

The absence of any recent Yahoo Finance headlines for AIOS despite it ranking as the sixth-biggest loser on September 1, 2026, is noteworthy. A nearly 28% single-day plunge in a NASDAQ-listed stock usually coincides with material corporate news—earnings results, guidance revisions, regulatory issues, leadership changes, or major contract losses—or broad market stress. Since no such headline is documented here, the move may reflect a delayed announcement that has not yet appeared in the RSS feed, a technical breakdown in a thinly traded stock, an undisclosed insider transaction, or a rumor circulating outside mainstream financial media. Without additional information about NiSun's sector exposure, share float, or recent investor relations activity, the underlying catalyst remains speculative.

VWAV

VisionWave Holdings, Inc.Industrials

$0.62−$0.23

-27.1%

NASDAQ · Mkt cap $36 M

VisionWave announced an update on its pending acquisition of C.M. Composite Materials Ltd. with a September 2026 close target, but the headline excerpt does not disclose details that would explain a 27% single-day drop; market concern likely centers on deal timing, financing uncertainty, or undis…

The provided headline confirms VisionWave issued an acquisition update on August 31st regarding C.M. Composite Materials, a supplier of structural components for defense systems. The stated goal is vertical integration of the supply chain for unmanned systems, with a September close targeted. However, the headline text is truncated and does not contain the full announcement details. A 27% intraday decline on an M&A update is unusual unless the release contained negative revisions to deal terms, financing contingencies, timeline slippage, or material operational headwinds at either company. It is also possible the market reacted to dilution expectations, deal structure unfavorable to existing shareholders, regulatory concerns tied to defense contracts, or worse-than-expected recent operational results disclosed alongside the update. Without the complete press release text, the specific catalyst remains unclear.

LHSW

Lianhe Sowell International Group Ltd Ordinary SharesTechnology

$2.91−$0.97

-24.9%

NASDAQ · Mkt cap $9.6 M

No news headlines were found in the last 48 hours, so the 24.92% drop cannot be directly attributed to a specific announced event. The cause is unknown and could reflect technical selling, delayed news, sector pressure, or other market factors.

The absence of recent headlines makes it impossible to pinpoint a specific catalyst for LHSW's sharp decline. A drop of this magnitude on a microcap or thinly traded stock like Lianhe Sowell typically reflects either a significant company-specific event that has not yet reached major news wires, a technical reversal following an earlier run-up, accumulation of negative sentiment or rumors in smaller forums, or broader sector/market selloff affecting similar issuers. Without access to the company's investor relations announcements, SEC filings made in the past 48 hours, or details about trading volume and technicals, we cannot rule out any of these categories. The stock's rank as the eighth biggest loser suggests material selling pressure, but without news evidence, the underlying reason remains speculative.

CDT

Conduit Pharmaceuticals IncHealthcare

$1.40−$0.42

-24.6%

SBXD.WT

SilverBox Corp IV WT

$0.10−$0.03

-24.6%

DBGI

Digital Brands Group, Inc.Consumer Cyclical

$4.84−$1.56

-24.4%

NASDAQ · Mkt cap $6.8 M

Digital Brands Group announced execution of a $3.3 million binding cash agreement through year-end 2026, but this appears to have triggered a sharp 24% sell-off, likely reflecting investor concern about dilution, financing terms, or the company's cash position underlying the need for such an arra…

The headline announces a binding contract for $3.3 million in guaranteed cash running through December 2026. On its surface, securing liquidity might appear positive, but the market's severe reaction suggests investors are interpreting this negatively. Possible explanations include concerns about dilution from equity issuance, unfavorable terms embedded in the financing agreement, or the revelation that the company requires this level of external cash support to operate through year-end, signaling financial stress. The announcement itself is truncated in the RSS feed, so the full details of the financing structure are not visible here. Without access to the complete press release, we cannot determine whether this involved equity dilution, debt, or asset-backed financing, all of which would carry different implications.

SKYH.WT

Sky Harbour Group Corporation

$0.28−$0.09

-24.3%

CANG

Cango Inc-KYFinancial Services

$1.84−$0.59

-24.2%

NYSE · Mkt cap $69 M

Cango announced Q2 2026 earnings with significant impairment charges that overshadowed cost-reduction wins, triggering a -24% sell-off as the market penalized the large writedown despite operational improvements.

The earnings call highlights reveal a mixed picture that likely prompted the sharp decline. While management achieved a 35% reduction in Bitcoin mining costs and is advancing AI infrastructure monetization, the announcement explicitly mentions "significant impairment charges" during a "challenging quarter." In equity markets, large impairment charges often signal asset quality deterioration, overvaluation of prior acquisitions, or operational challenges that management failed to anticipate. Although the operational metrics (cost cuts, AI strategy) are positive, impairments typically carry negative sentiment because they represent sunk losses and may foreshadow guidance cuts or margin pressure ahead. The magnitude of the one-day drop (ranked 13 biggest losers) suggests the impairment charge was material relative to the company's market cap or earnings expectations, and investors are likely repricing the stock downward to reflect a weaker underlying business reality beneath the cost-cutting narrative.

AEHL

Antelope Enterprise Holdings LimitedIndustrials

$5.00−$1.48

-22.8%

NASDAQ · Mkt cap $6.5 M

No news headlines were found in the last 48 hours, so the cause of AEHL's 22.78% decline cannot be pinned to a specific announced event; the drop may reflect technical selling, a delayed news item, or market reaction to untracked information.

No recent news headlines are available to explain AEHL's sharp 22.78% decline on September 1, 2026. Without access to earnings reports, guidance changes, regulatory announcements, or other material events, the catalyst remains unclear. For a micro-cap or less-liquid stock like AEHL, such drops could stem from several sources: a delayed or missed earnings release, insider selling, short-term technical breakdown, untracked news on alternative sources, or broader sector rotation. It is also possible a material announcement was made but did not appear in the RSS feed checked. Without additional context on the company's business, recent performance, or institutional interest, identifying the specific trigger is not possible from the evidence at hand.

IRHOR

Iron Horse Acquisitions Corp. II Rights

$0.15−$0.04

-22.6%

NASDAQ

Iron Horse Acquisition II rights fell 22.56% despite a positive announcement that the SPAC's target (Electra AI) won a battery intelligence contract with Mooving, suggesting market skepticism about deal completion or valuation rather than enthusiasm for the business win.

The headline on September 1st announced that Electra AI and Iron Horse Acquisition II were selected by Mooving to power battery intelligence across a battery-swapping network—a concrete contract win. However, this positive news coincided with a sharp 22.56% decline in IRHO rights, which is a substantial gap unit in a SPAC structure. The disconnect suggests the market is either pricing in deal execution risk, skeptical of the revenue potential from this contract, or responding to broader SPAC sentiment weakness. Rights are junior to common shares and warrant recovery only if the merger closes and the common appreciates significantly, so investors may be discounting the probability or magnitude of value creation. Alternatively, this could reflect a delayed market reaction to negative SPAC news from the prior 24 hours not captured in the headlines provided.

DUO

Fangdd Network Group Ltd

$0.58−$0.17

-22.3%

AMPGZ

Amplitech Group, Inc. Series B Right

$0.17−$0.05

-22.3%

NASDAQ

No news headlines were found in the last 48 hours to explain the 22.28% decline in AMPGZ, suggesting the drop may reflect broader market conditions, technical selling, or developments not yet captured in public headlines.

The complete absence of recent news headlines makes it impossible to identify a specific catalyst for today's sharp 22.28% loss in AMPGZ, a Series B rights offering security. AMPGZ is a derivative instrument tied to Amplitech Group's equity structure, and rights securities are inherently volatile and illiquid, often trading on technical factors and changes in the underlying stock's valuation. Possible explanations include a decline in the underlying Amplitech common stock (which would drag down the rights), negative sentiment toward the parent company that hasn't yet appeared in major financial news feeds, forced selling by holders facing margin calls or portfolio rebalancing, or simply thin trading volume that allows small trades to create large percentage swings. Without news coverage, we cannot distinguish between these scenarios.

BIDWR

Tribeca Strategic Acquisition Corp. Rights

$0.10−$0.03

-21.8%

BPTH

Bio-Path Holdings Inc

$0.02−$0.01

-21.7%

SQFT

Presidio Property Trust IncReal Estate

$1.54−$0.42

-21.4%

NASDAQ · Mkt cap $2.1 M

No news headlines were found in the last 48 hours to explain SQFT's 21.43% drop, so the cause remains unclear without additional reporting or company announcements.

The absence of any headlines in the 48 hours preceding the large single-day decline makes it difficult to identify a specific catalyst for the 21.43% move in SQFT. Presidio Property Trust is a real estate investment trust, and such securities can be sensitive to interest rate changes, credit market conditions, occupancy data, or property valuation adjustments. The sharp drop could reflect a delayed market reaction to company-specific news not yet picked up by major financial wires, a broader sector rotation out of REITs, or negative earnings or guidance news that may not yet have appeared in the RSS feed. Without confirmed reporting, the actual cause remains speculative.

KALA

Kala Pharmaceuticals IncHealthcare

$0.53−$0.14

-21.2%

RZLV

Rezolve AI LimitedTechnology

$2.40−$0.63

-21.2%

NASDAQ · Mkt cap $1.2 B

Rezolve AI reported explosive 1,970% revenue growth to $130.8M in H1 2026 with major partnerships including Google and Microsoft, but the stock crashed 21% because net losses widened significantly, offsetting the revenue headline and signaling profitability concerns despite growth.

Rezolve AI announced first-half 2026 results showing remarkable top-line expansion driven by infrastructure partnerships with Microsoft, Google, TCS, and Tech Mahindra, with customer base exceeding 1,640. The company reaffirmed approximately $360 million in full-year 2026 revenue guidance. However, multiple headlines explicitly cite widening net losses as the primary reason for the sharp sell-off, with one article titled "Why Rezolve AI Stock Crashed Today" stating that sales growth alone was insufficient to prevent the decline. The market's reaction reflects a classic growth-versus-profitability tension: while the 20-fold revenue increase is striking, investors punished the company for deteriorating losses, suggesting concerns that rapid scaling is consuming capital faster than expected and raising questions about the path to sustainable profitability despite the strategic validation from major tech vendors.

FIXX

Homology Medicines Inc

$11.78−$3.09

-20.7%

LTCH

Latch, Inc.Technology

$0.15−$0.04

-20.3%

NASDAQ · Mkt cap $31 M

No news headlines were available in the last 48 hours to explain LTCH's 20% decline, so the cause remains unclear without additional reporting.

Latch is a commercial building access and security software company, and a 20% single-day drop of this magnitude typically requires a material catalyst. The absence of any news in the Yahoo Finance RSS feed over the past two days is notable but does not rule out causation. Possibilities include a missed earnings report, negative guidance revision, executive departure, or adverse industry/competitive news that has not yet propagated to major news aggregators. Alternatively, the move could reflect technical selling pressure in a thinly traded stock, cumulative negative sentiment from earlier weeks, or a delayed market reaction to information disclosed after the news cycle closed. Without confirmed reporting, attributing this decline to a specific event would be speculative.

WTER

Alkaline Water Co Inc-TheConsumer Defensive

$0.02−$0.00

-20.0%

NASDAQ · Mkt cap $1.1 M

No news headlines were published in the last 48 hours, making the 20% intraday drop impossible to attribute to a specific catalyst. The decline likely stems from technical selling, low-float liquidity dynamics, or delayed news not yet indexed by Yahoo Finance RSS.

With no recent news available, we cannot directly explain the 20% drop on September 1st. Alkaline Water is a micro-cap stock trading at $0.02 with historically thin liquidity, characteristics that make it vulnerable to momentum selling and technical breaks independent of company-specific news. Possible explanations include: (1) a broader market sell-off affecting low-priced speculative names disproportionately, or (2) a delayed announcement (SEC filing, insider activity, or clinical/regulatory setback) that has not yet propagated to major news aggregators. Without headline confirmation, both remain educated guesses rather than established facts.

XXII

22nd Century Group IncConsumer Defensive

$2.61−$0.60

-18.7%

NASDAQ · Mkt cap $1.4 M

XXII fell 18.69% on the same day the CEO issued a positive mid-year letter highlighting improved margins, retail expansion to 5,000 outlets, and accelerating growth, suggesting the market either expected more aggressive guidance or reacted to a confounding external factor not captured in the head…

The provided headline is decidedly bullish: the CEO emphasizes improved gross margin, significant retail distribution expansion to approximately 5,000 outlets, a substantial addressable market opportunity exceeding 50 billion dollars, and accelerating commercial execution with same-store sales growth of 22 percent. This messaging would typically support a stock price increase rather than an 18.69 percent decline. The disconnect between positive operational narrative and sharp downside suggests either (a) the full letter contained forward guidance that disappointed relative to market expectations, (b) the market had already priced in these developments and was awaiting more aggressive targets, or (c) an unrelated catalyst such as sector headwinds, insider selling, short-squeeze unwinding, or a competing announcement drove the sell-off. Without access to the full shareholder letter text or concurrent market-wide moves, the precise cause remains partially obscured.

CNXU

Conexeu Sciences Inc.Healthcare

$5.86−$1.31

-18.3%

NASDAQ · Mkt cap $240 M

CNXU dropped 18.33% on September 1st with no material company-specific news disclosed; the conference schedule announcement and weight-loss drug industry commentary appear unrelated to the severity of the decline.

The two headlines available do not explain an 18% single-day loss. Conexeu's own news is a routine conference schedule announcement for September and October 2026, which is administrative in nature and not typically a negative catalyst. The broader industry commentary about weight-loss drugs and aesthetic medicine market growth is positive contextual framing for the sector but contains no specific information about Conexeu or any adverse development. As a preclinical-stage biotech company, CNXU is highly sensitive to clinical trial results, regulatory decisions, financing events, and investor sentiment shifts. The lack of disclosed negative news suggests the move may reflect a delayed market reaction to unreported information, technical selling pressure, short covering, or broader biotech sector weakness on the snapshot date. Without access to intraday alerts or pre-market developments, the specific trigger remains unknown.

ADBT

Advasa Holdings, Inc.

$3.69−$0.81

-18.1%

ALISR

Calisa Acquisition Corp Right

$0.65−$0.14

-17.7%

NASDAQ

No news headlines were found in the last 48 hours, but ALISR is a SPAC rights unit, which typically decays in value as redemption deadlines approach and investor interest wanes, likely explaining the sharp 17.72% single-day drop.

No recent news headlines were available to establish a specific catalyst for today's decline. However, ALISR is a right issued by Calisa Acquisition Corp, a special purpose acquisition company. SPAC rights characteristically lose value over time as they approach expiration and as investors redeem their shares or lose interest in the underlying deal. Rights are highly sensitive to changes in the parent SPAC's trading price, redemption dynamics, and deal certainty. The sharp single-day loss is consistent with either deteriorating sentiment around the sponsor or merger target, a change in deal terms, an approaching redemption deadline, or simply the structural decay inherent to these instruments as time value erodes. Without headlines or specific deal news, the most probable explanation is technical pressure related to the expiring value of the rights themselves rather than an external news event.

CRDO

Credo Technology Group Holding Ltd Ordinary SharesTechnology

$206.95−$39.77

-17.5%

NASDAQ · Mkt cap $32 B

Credo Technology fell 17.46% despite beating fiscal Q1 earnings and revenue estimates, suggesting the stock was priced for perfection and the market sold on the results rather than being disappointed by them.

The headlines establish that Credo reported earnings and revenue beats on September 1st in extended trading, yet the stock fell sharply anyway. Multiple sources explicitly note the disconnect between strong results and negative price action. One headline directly addresses valuation, stating the stock has delivered large gains over three years and is trading at a premium based on both market multiples and DCF analysis. This points to a sell-the-news dynamic where the market had already priced in strong execution, leaving minimal upside surprise. The broader market context shows weakness across tech stocks on September 1st due to geopolitical concerns and oil prices, but Credo's 17% drop far exceeds typical sector rotation. The most likely explanation is that investors used the earnings beat as an exit point given rich valuation, rather than being surprised by disappointing fundamentals.

SUPX

Super X AI Technology LimitedTechnology

$8.06−$1.67

-17.1%

NASDAQ · Mkt cap $283 M

No news headlines were found in the last 48 hours for SUPX, so the 17.15% drop cannot be attributed to any reported event. The decline likely reflects sector rotation, technical selling, or undisclosed market developments.

The absence of recent news headlines makes it impossible to identify a specific catalyst for SUPX's sharp 17.15% decline. For an AI technology stock trading on NASDAQ, potential drivers could include broad sector weakness in AI equities, profit-taking after a prior rally, technical breakdown through a key support level, or delayed coverage of an earlier announcement not yet indexed by the news feed. Without access to real-time trading data, after-hours news, or company-specific developments, we cannot distinguish between these scenarios. The stock's rank as the 31st biggest loser suggests the move was significant but not unprecedented for a single trading day.

NCRA

Nocera Inc.Consumer Defensive

$2.32−$0.48

-17.1%

NASDAQ · Mkt cap $3.2 M

No news headlines were available in the last 48 hours for NCRA, so the 17% decline cannot be attributed to a specific announced event. The drop likely stems from technical selling, market-wide pressure, or untracked developments.

Despite the sharp 17% single-day decline that ranked NCRA among the top 32 losers on NASDAQ, no relevant news headlines appeared in the Yahoo Finance RSS feed during the 48-hour window preceding the snapshot. This absence of reported catalysts makes attribution difficult. For a micro-cap or thinly-traded stock like NCRA, declines of this magnitude can occur due to several non-news factors: technical breakdown below a support level, liquidation by a major holder, short-seller activity, or delayed reporting of company announcements not yet picked up by major news aggregators. Without access to after-hours reports, SEC filings, or trading data, pinpointing the specific cause requires inference rather than evidence. The lack of visible news does not rule out meaningful developments; it may simply indicate timing gaps in news distribution or that the move preceded formal disclosure.

MDB

MongoDB IncTechnology

$435.29−$77.89

-17.0%

NASDAQ · Mkt cap $34 B

MongoDB beat both earnings and revenue estimates with strong guidance, but the stock fell 17% in after-hours trading—a classic case of "sell the news" or profit-taking despite fundamental strength.

The headlines establish that MongoDB reported Q2 fiscal 2027 results on September 1, 2026, with adjusted EPS of $1.90 beating consensus of $1.61 (18.75% surprise), revenue of $771.8 million beating expectations (5.20% surprise), and year-over-year sales growth of 30.5%. The company also raised fiscal 2027 guidance. Multiple sources explicitly note the disconnect: the stock tumbled despite these beats, with one headline directly stating "sell the news" dynamics. This pattern suggests investors had already priced in strong performance and used the earnings release as a trigger to lock in gains rather than being disappointed by fundamentals. The pre-earnings narrative mentioned unproven AI upside as a watch point; the strong results may have met but not exceeded elevated expectations built into the stock price ahead of the print.

EHTH

eHealth Inc

$0.94−$0.19

-17.0%

FBYD

Falcon's Beyond Global, Inc. - Class A Common StockIndustrials

$7.51−$1.54

-17.0%

NASDAQ · Mkt cap $387 M

No news headlines were found in the last 48 hours, so the 17% decline likely stems from a delayed announcement, technical selling, or sector-specific pressure unrelated to recent public disclosures.

Falcon's Beyond Global experienced a sharp 17% single-day loss while ranking among the market's 35 biggest losers, yet no news surfaced in the prior 48 hours to explain the move. This disconnect suggests several possibilities. First, a material announcement (earnings, strategic update, or operational setback) may have occurred outside the Yahoo Finance RSS feed window or released after market close. Second, the decline could reflect technical or momentum-driven selling, particularly if the stock had run up recently or faces overhead resistance. Third, sector headwinds affecting entertainment, theme parks, or technology-enabled venue operators could be at play. Falcon's Beyond operates in experiential entertainment and virtual reality venues, a niche that can be sensitive to consumer spending trends, investor sentiment shifts, or competitive pressures. Without a specific news catalyst in the public record, attribution remains speculative.

PPCB

Propanc Biopharma, Inc.Healthcare

$1.12−$0.22

-16.7%

NASDAQ · Mkt cap $2.6 M

No news headlines were found in the last 48 hours, so the 16.67% decline in PPCB cannot be directly attributed to a specific announced event; the drop likely reflects either technical selling, broad biotech sector weakness, or a delayed market reaction to earlier information.

The absence of recent news headlines makes it difficult to identify a specific catalyst for the sharp decline. Propanc Biopharma is a clinical-stage oncology biotech company, and stocks in this category are inherently volatile and sensitive to multiple factors outside of daily news cycles. The move could reflect profit-taking after a recent run, technical breakdown through a support level, broader weakness in the biotech sector, or a delayed market reaction to clinical trial results, partnership updates, or regulatory communications that may not have appeared in the RSS feed captured. Without concrete information, any explanation remains speculative.

SPEGR

Silver Pegasus Acquisition Corp Rights.

$0.20−$0.04

-16.7%

NASDAQ

No news headlines were available in the last 48 hours to explain the 16.67% decline in Silver Pegasus Acquisition Corp Rights, making the immediate cause unclear, though rights offerings are inherently volatile instruments sensitive to sentiment shifts around the underlying SPAC.

The absence of any news in the past two days means we cannot point to a specific catalyst such as an earnings miss, merger update, or management change. Silver Pegasus Acquisition Corp Rights are a specialized security tied to a SPAC structure, meaning their value depends heavily on sentiment around the parent SPAC's prospects and the likelihood of a successful merger announcement or completion. Rights offerings typically trade with higher volatility than common stock because their intrinsic value derives entirely from the option they represent. The decline could reflect a broader sector pullback in blank-check companies, deteriorating confidence in the SPAC's deal timeline or target, market-wide risk-off sentiment, or simply technical selling in a thinly traded security. Without news, attribution remains speculative.

ENOV

Enovis CorporationHealthcare

$20.53−$4.08

-16.6%

NYSE · Mkt cap $1.1 B

Enovis announced a €155M binding offer to acquire eCential Robotics on September 1st, likely triggering a selloff due to acquisition cost concerns, dilution fears, or investor skepticism about the strategic fit and integration risks.

The headline evidence shows Enovis made a major M&A announcement on the day of the price drop, committing to acquire eCential Robotics, a surgical robotics developer, for €155 million. The company framed this as an expansion of enabling-technology capabilities and creation of a robotics center of excellence. Large acquisitions in healthcare technology frequently trigger immediate selloffs when investors question valuation, integration complexity, debt impact, or whether the target's technology justifies the premium. Without details on funding structure, accretion timeline, or synergy assumptions provided in the headlines, market participants may have immediately marked down the stock based on typical M&A dilution concerns or a mismatch between announced ambitions and perceived execution risk in robotics integration.

ZTG

Zenta Group Company LimitedIndustrials

$0.76−$0.15

-16.1%

NASDAQ · Mkt cap $30 M

ZTG dropped 16.11% on September 1st with no headlines in the last 48 hours, making the specific cause unclear; the move likely stems from a delayed news release, technical selling, or general market sentiment affecting micro-cap stocks.

No news headlines were available in the last 48 hours preceding this 16% single-day decline, which limits our ability to pinpoint a concrete catalyst. ZTG is a micro-cap NASDAQ-listed stock where price movements of this magnitude can occur from several sources: a material announcement released outside the monitored news feed, accumulation of sell orders from institutional or retail holders, technical breakdown through support levels, or sector-wide pressure affecting similar companies. Without access to company filings, insider activity, or social media sentiment, we cannot determine whether this reflects new information, technical chart patterns, or a broader rotation away from the stock. The absence of capturing the triggering event in the news aggregator itself could indicate a delayed publication or an event announced through non-traditional channels.

MIMI

Mint Incorporation LimitedIndustrials

$0.70−$0.13

-16.0%

NASDAQ · Mkt cap $14 M

MIMI fell 15.98% on Tuesday with no news headlines available in the last 48 hours, suggesting the move was driven by technical selling, market-wide pressure, or an unannounced development not yet captured by major news feeds.

There are no recent news headlines available to explain the sharp 15.98% decline in MIMI on September 1, 2026. The stock ranked among the day's 40 biggest losers, indicating a material selloff. Without confirmed news, the cause could fall into several categories: technical breakdown or stop-loss cascade in a low-priced equity, sector-wide weakness affecting the stock's industry peer group, insider or institutional selling not yet disclosed, or a rumor or development that preceded formal news announcement. Low-priced stocks like MIMI trading at $0.70 are particularly susceptible to momentum-driven selling and lower trading liquidity, which can amplify intraday moves. An earnings miss, delisting warning, or executive departure could trigger this magnitude of drop and may not yet be reflected in the news feeds sampled.

NTCL

NETCLASS TECHNOLOGY INC Class A Ordinary SharesTechnology

$1.92−$0.36

-15.8%

NASDAQ · Mkt cap $3.3 M

No news headlines were published in the last 48 hours about NTCL, so the 15.79% drop cannot be attributed to a specific disclosed catalyst. The decline likely stems from technical selling, market sentiment shifts, or undisclosed material information.

The absence of recent news makes attribution difficult. NETCLASS TECHNOLOGY INC is a small-cap NASDAQ stock trading at $1.92, and stocks at this price point and market-cap level are often subject to liquidity constraints, technical momentum reversals, and outsized moves on light volume without accompanying news flow. The drop could reflect several possibilities: profit-taking after a prior rally, sector-wide weakness in technology stocks, options expiration activity, short covering reversals, or delayed market reaction to older news not captured in the 48-hour window. Without confirmed headlines connecting to specific events like earnings misses, guidance cuts, insider sales, regulatory action, or competitive developments, any explanation remains speculative. The size of the move (41st biggest loser) suggests something material, but no public disclosure is evident.

OFAL

OFA GroupIndustrials

$0.63−$0.12

-15.7%

PSQL

Pasqal Holding SA

$15.56−$2.81

-15.7%

BRNX

Brenx Ltd.

$3.60−$0.66

-15.5%

BTAI

Bioxcel Therapeutics IncHealthcare

$0.14−$0.02

-15.4%

NASDAQ · Mkt cap $26 M

Teva Pharmaceuticals announced it is acquiring key BioXcel assets including the approved drug Igalmi for up to $125 million, likely perceived as an unfavorable valuation or strategic setback that triggered the 15.42% single-day drop.

The headlines establish that Teva made a bid to acquire BioXcel assets, obtaining worldwide rights to Igalmi (an approved neuroscience treatment) and the investigational compound BXCL501 for up to $125 million. For a company trading at $0.14 per share, this transaction likely signals either a distressed valuation scenario, a forced partial asset sale, or market skepticism about the deal terms and BioXcel's standalone prospects. The use of the word "bid" in one headline and the relatively modest deal size for a marketed pharmaceutical asset suggest investors may view this as an unfavorable outcome. Without confirmation of the company's market capitalization or existing debt, a definitive assessment of deal value is impossible, but the immediate sharp decline indicates market participants interpreted the news negatively, interpreting it as dilutive or indicative of deteriorating business conditions.

PFAI

Pinnacle Food Group Limited Class A Common SharesConsumer Defensive

$3.04−$0.44

-15.3%

NASDAQ · Mkt cap $35 M

No news headlines were found in the last 48 hours for PFAI, so the 15.33% drop likely reflects either broader market weakness, sector-specific pressure on food companies, or an undisclosed event not yet captured in news feeds.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for the 15.33% decline. For a food company stock trading at $3.04, typical drivers of single-day losses of this magnitude include earnings misses, disappointing guidance, negative FDA or regulatory developments, macro headwinds affecting food inflation or consumer demand, or company-specific operational setbacks. Given that PFAI is ranked 46th among daily losers, the move suggests material negative sentiment rather than pure noise. Without access to intraday catalysts, earnings releases, insider transactions, or analyst downgrades that may have occurred outside the Yahoo Finance RSS feed window, the most likely categories are either a delayed earnings or guidance announcement, sector rotation away from consumer staples, or firm-specific news that has not yet propagated to major headlines.

GPUS

Hyperscale Data, Inc.Industrials

$0.24−$0.04

-15.2%

NYSE · Mkt cap $31 M

Alset AI Ventures (GPUS) fell 15.25% on August 31st following the release of fiscal Q3 2026 results showing $4.1 million in unrealized non-cash investment gains, which may have disappointed market expectations for more substantial operating or cash-backed earnings.

The only headline provided is a Q3 2026 earnings report from Alset AI Ventures, the parent company of GPUS. The press release emphasizes a $4.1 million unrealized, non-cash investment gain and mentions total assets increased 82.4 million, suggesting asset growth. However, the headline excerpt is incomplete and does not provide the full earnings picture—notably missing revenue figures, operating income, or guidance commentary that typically drive post-earnings moves. The distinction between unrealized non-cash gains and actual cash earnings or revenue is material; investors often react negatively to earnings heavily weighted toward paper gains rather than operational performance. Without the complete earnings release details, we cannot definitively rule out that other metrics in the full report—such as revenue decline, widening losses, or negative guidance—were the actual trigger for the 15.25% decline.

XTIA

XTI Aerospace, Inc.Industrials

$1.14−$0.20

-15.2%

NASDAQ · Mkt cap $51 M

XTI Aerospace received a Nasdaq deficiency notice on August 31st, triggering a 15.17% stock price decline on September 1st as investors reacted to the regulatory warning that likely concerns compliance issues or listing standards.

The headline confirms that XTI Aerospace announced receipt of a Nasdaq deficiency notice on August 31st. The full details of the deficiency are not provided in the excerpt, but Nasdaq deficiency notices typically signal that a company has failed to meet one or more listing standards, such as minimum bid price, stockholder equity, market capitalization, or corporate governance requirements. Such notices create material uncertainty about the company's ability to maintain its listing and often trigger sharp sell-offs as investors price in delisting risk and the operational challenges that prompted the deficiency. The timing between the announcement and the 15% single-day drop is consistent with market reaction to serious regulatory compliance warnings.

CYCU

Cycurion, Inc. Common StockTechnology

$3.14−$0.56

-15.1%

NASDAQ · Mkt cap $7.9 M

No news headlines were found in the last 48 hours, so the 15% decline cannot be directly attributed to a reported event. The drop likely stems from technical selling, sector headwinds, or an untracked announcement.

Despite the significant 15.14% single-day decline that placed CYCU among the top 49 losers on NASDAQ, no recent news headlines are available to explain the move. This absence of reported catalysts makes root-cause analysis difficult. The stock could be experiencing technical selling pressure following a prior rally, sector-wide declines in its industry, or a delayed market reaction to an announcement not yet captured in major news feeds. Alternatively, the drop could reflect insider developments, regulatory concerns, or liquidity events that have not yet been widely reported. Without access to company filings, social media chatter, or press releases issued outside major RSS feeds, attributing the move to a specific fundamental event is not possible based on the evidence provided.

LABT

Lakewood-Amedex Biotherapeutics Inc.Healthcare

$2.75−$0.47

-15.1%

NASDAQ · Mkt cap $3.8 M

No news headlines were published in the last 48 hours for LABT, so the 15% decline cannot be directly attributed to a disclosed event. Biotech microcaps often experience sharp moves on unannounced developments, technical selling, or broader sector weakness.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for LABT's 15% single-day drop. This is a common pattern with small-cap biotech stocks, which tend to be illiquid and sensitive to multiple potential triggers that may not generate immediate press coverage: clinical trial setbacks reported through internal channels, delayed regulatory decisions, insider selling, short-seller reports, sector rotation out of smaller biotechs, or technical breakdown below key support levels. Without access to SEC filings, insider transactions, or broader market context for that date, we cannot distinguish between these possibilities. The stock's rank as the 50 biggest loser suggests a material repricing, but the cause remains opaque from public headlines alone.